Rift Valley fever monoclonal antibody therapeutic - IDBiologics
Latest Information Update: 22 Aug 2024
Price :
$50 *
At a glance
- Originator IDBiologics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rift Valley fever
Most Recent Events
- 29 Jul 2024 Preclinical research in Rift Valley fever (Prevention) in USA (Parenteral) before July 2024 (IDBiologics pipeline, July 2024)
- 29 Jul 2024 Preclinical research in Rift Valley fever in USA (Parenteral) before July 2024 (IDBiologics pipeline, July 2024)
- 29 Jul 2024 INBiologics plans to submit IND application to regulatory authority in the second half of 2024 (INBiologics pipeline, July 2024)